SGLT2 Diabetes Drugs Linked to 39% Lower Dementia Risk in People With Mood Disorders
A large VA study finds SGLT2 inhibitors cut dementia risk by nearly 40% in older adults with depression, bipolar disorder, or schizophrenia.
Summary
A new study published in JAMA Network Open found that SGLT2 inhibitors — a class of diabetes drugs — were associated with a significantly lower risk of developing dementia in older adults with major depression, bipolar disorder, or schizophrenia. Using data from over 112,000 veterans aged 65 and older, researchers found that those who used SGLT2 inhibitors were 39% less likely to develop dementia compared to non-users. The drugs were also linked to fewer psychiatric emergency department visits. People with serious psychiatric conditions face a higher baseline dementia risk and are rarely included in prevention research, making this finding especially significant for a historically underserved population.
Detailed Summary
People living with serious psychiatric conditions such as major depression, bipolar disorder, and schizophrenia already face a substantially elevated risk of developing dementia compared to the general population. Yet this group is consistently underrepresented in dementia prevention research, leaving a major gap in evidence-based care. A new study aimed to address that gap directly.
Researchers from NYU Grossman School of Medicine used a target trial emulation framework drawing on Department of Veterans Affairs healthcare data from 2016 to 2024. They identified 112,725 adults aged 65 and older with qualifying psychiatric diagnoses and no prior dementia. Over a median follow-up of 3.3 years, they tracked whether initiating SGLT2 inhibitor treatment — drugs originally developed for type 2 diabetes — changed the likelihood of developing dementia or requiring emergency psychiatric care.
The results were striking. In the intention-to-treat analysis, SGLT2 inhibitor users had 39% lower odds of developing all-cause dementia (OR 0.61) and 20% fewer psychiatric emergency department visits (OR 0.80). A stricter per-protocol analysis showed even stronger protection against dementia (OR 0.54) and psychiatric hospitalizations (OR 0.56). The sample was predominantly male (92.8%), reflecting the VA population, with a median age of 74.1 years.
The researchers propose several mechanisms. SGLT2 inhibitors may protect the brain by improving energy metabolism, enhancing mitochondrial function, and reducing neuroinflammation — pathways increasingly recognized as central to neurodegeneration. These findings align with a growing body of evidence linking metabolic health to brain aging and cognitive decline.
Important caveats apply. This was an observational study using a predominantly male veteran population, limiting generalizability. The VA cohort is not representative of the broader public, and confounding factors may influence results. Randomized controlled trials are needed to confirm causality before clinical recommendations can be made.
Key Findings
- SGLT2 inhibitor use was linked to 39% lower odds of all-cause dementia in adults with major psychiatric disorders.
- Per-protocol analysis showed even stronger protection, with 46% reduced dementia odds among consistent SGLT2 inhibitor users.
- Psychiatric emergency department visits were 20% lower among SGLT2 inhibitor users in the intention-to-treat analysis.
- People with depression, bipolar disorder, or schizophrenia are at high dementia risk but are rarely studied in prevention trials.
- SGLT2 inhibitors may protect the brain via improved energy metabolism, mitochondrial function, and reduced inflammation.
Methodology
This is a news report summarizing a peer-reviewed study published in JAMA Network Open, a credible open-access journal. The study used a target trial emulation design — a rigorous observational method — based on VA healthcare data covering 2016 to 2024. While not a randomized controlled trial, the methodology is considered a strong approach for real-world evidence generation.
Study Limitations
The study population is 92.8% male veterans, severely limiting generalizability to women and the general public. As an observational study, causality cannot be confirmed and residual confounding remains possible. Randomized trials in diverse populations are needed before clinical guidelines can incorporate these findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: